These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 26077516)
1. The prevalence and determinants of drug-resistance-associated mutations in the HIV-1-infected MSM population of Henan Province in China. Hou LJ; Wang HW; Duan SP; Zhuo Y; Zhou YC; Wu HJ; Shen BS Arch Virol; 2015 Aug; 160(8):2051-61. PubMed ID: 26077516 [TBL] [Abstract][Full Text] [Related]
2. New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China. Zhao B; Han X; Dai D; Liu J; Ding H; Xu J; Chu Z; Bice T; Diao Y; Shang H AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1047-53. PubMed ID: 21417755 [TBL] [Abstract][Full Text] [Related]
3. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns. Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J Virol J; 2015 Nov; 12():187. PubMed ID: 26578099 [TBL] [Abstract][Full Text] [Related]
4. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M; Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623 [TBL] [Abstract][Full Text] [Related]
5. HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China. Lu X; Zhao H; Zhang Y; Wang W; Zhao C; Li Y; Ma L; Cui Z; Chen S AIDS Res Ther; 2017 Jan; 14(1):4. PubMed ID: 28114955 [TBL] [Abstract][Full Text] [Related]
6. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy. Saini S; Bhalla P; Gautam H; Baveja UK; Pasha ST; Dewan R J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):203-9. PubMed ID: 21990611 [TBL] [Abstract][Full Text] [Related]
7. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037 [TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
9. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India. Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504 [TBL] [Abstract][Full Text] [Related]
10. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation. Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342 [TBL] [Abstract][Full Text] [Related]
11. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations. Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857 [TBL] [Abstract][Full Text] [Related]
12. Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. Youmans E; Tripathi A; Albrecht H; Gibson JJ; Duffus WA South Med J; 2011 Feb; 104(2):95-101. PubMed ID: 21206421 [TBL] [Abstract][Full Text] [Related]
13. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016 [TBL] [Abstract][Full Text] [Related]
14. Limited evolution but increasing trends of primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-naive HIV-1-infected individuals in India. Neogi U; Gupta S; Palchaudhuri R; Rao SD; Shastri S; Diwan V; Laishram RS; De Costa A; Shet A Antivir Ther; 2014; 19(8):813-8. PubMed ID: 24699043 [TBL] [Abstract][Full Text] [Related]
15. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali. Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120 [TBL] [Abstract][Full Text] [Related]
16. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V; J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728 [TBL] [Abstract][Full Text] [Related]
17. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China]. Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383 [TBL] [Abstract][Full Text] [Related]
18. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929 [TBL] [Abstract][Full Text] [Related]
19. [Study on HIV-1 drug resistance profile of 257 AIDS patients with failure on the first-line antiretroviral treatment in Henan]. Liu J; Cui WG; Liu CH; Zhu XP; Dou ZH; Wu YS; Zhu Q; Wang Z Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Mar; 33(3):318-22. PubMed ID: 22613387 [TBL] [Abstract][Full Text] [Related]
20. Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. Santoro MM; Svicher V; Gori C; Zaccarelli M; Tozzi V; Forbici F; D'Arrigo R; Trotta MP; Bellocchi MC; Visco-Comandini U; Cenci A; Bertoli A; Narciso P; Antinori A; Perno CF; Ceccherini-Silberstein F New Microbiol; 2006 Apr; 29(2):89-100. PubMed ID: 16841549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]